Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance ECT vs Clozapine in Treatment-Resistant Schizophrenia
NCT03807882Phase 4Completed
- Sponsor
- AIIMS New Delhi
- Start
- Feb 2019
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by AIIMS New Delhi. Primary endpoint: Positive and Negative Syndrome Scale at 24 weeks. Started Feb 2019; status: completed.
Beyond the preview
Go deeper on NCT03807882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807882.